Health Care

Vera Therapeutics insider activity shows a net buy‑up and routine tax‑related sales, reflecting CEO confidence amid a volatile stock and a promising immunology pipeline.

Arcellx insider activity: CFO’s recent sale reflects tax‑linked RSU vesting, not a bearish bet, amid Gilead takeover talks and rising stock.

Insider buying surges at ProMIS Neurosciences as ABG V‑SIV IX and AB G Management purchase 700k shares, betting on PMN310 milestone data to lift shares.

CEO Thomas Schoenherr’s modest buy of Tempus AI stock signals renewed confidence in its AI‑driven diagnostics, hinting at a potential upside amid market volatility.

Exagen CEO’s tax‑related sale is routine, but insider selling trends highlight cautious management—investors should watch Q4 earnings for real impact.

Insider buying boosts optimism for Axsome’s pipeline, as Mark Coleman’s 6,250‑share purchase signals confidence in commercial growth and Phase 3 trials.

iRhythm insider sale: Chief Accounting Officer Marc Wade sells 280 shares at $140.91, signalling a routine plan‑based move amid a dip‑back‑to‑value scenario.

Insider buying at Personalis Inc. shows CFO Tachibana’s confidence; zero‑cost option exercise hints at future growth but current negative earnings warn of risk.

Insightful insider sale of Xeris Biopharma shares shows cautious liquidity strategy amid recent revenue beat, urging investors to watch upcoming clinical milestones for true upside.

Alkermes insider buying signals management confidence amid Avadel acquisition; learn what Parisi Samuel Joseph’s trades mean for investors.